Siga Technologies, Inc. has announced that the U.S. Department of Health and Human Services exercised a procurement option for the delivery of approximately $113 million of oral TPOXX® treatment courses. This order reflects a continuing effort to enhance orthopoxvirus preparedness.
The chief executive officer, Diem Nguyen, emphasized that this significant order from the U.S. government, combined with previous orders from both domestic and international customers, will contribute to enhancing orthopoxvirus preparedness and supporting consistent action to ensure public health from various threats. The company views this as fulfilling its responsibility to global health security while generating attractive returns for the company and its shareholders.
Siga Technologies, Inc. is a commercial-stage pharmaceutical company focused on the development of innovative medicines to treat and prevent infectious diseases, with a primary focus on orthopoxviruses. Its flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe and the UK for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications. The market has reacted to these announcements by moving the company's shares 3.7% to a price of $9.39. If you want to know more, read the company's complete 8-K report here.
